CAR-T play­er Juno grabs a PhII com­bo drug in $10M add-on deal

Fresh on the heels of a brief but con­tro­ver­sial FDA hold on its lead ther­a­py, Juno has made a small, strate­gic ac­qui­si­tion, buy­ing Boston-based Re­dox …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.